title: Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999. Groupe d'Epidémiologie Clinique du Syndrome d'Immunodéficience Acquise en Aquitaine.
abstract: The objective of this study was to estimate the prevalence of and risk factors for clinical lipodystrophy (LD) and metabolic disorders in human immunodeficiency virus (HIV) type 1-infected patients. A cross-sectional survey of the Aquitaine Cohort was performed in January 1999. The clinical diagnosis of LD was categorized as fat wasting (FW), peripheral fat accumulation (FA), and mixed syndromes (MS). Of the 581 patients studied, 61% were treated with protease inhibitors. The overall prevalence of LD was 38% (95% confidence interval [CI], 32-42): prevalence of FW was 16% (95% CI, 13-18); of FA, 12% (95% CI, 10-15); and of MS, 10% (95% CI, 8-13). The prevalences of metabolic abnormalities were 49% (95% CI, 44-53) for lipid disorders and 20% (95% CI, 17-23), for glucose disorders. Factors associated with LD were age (for FW and MS), male sex (for FW), AIDS stage (for MS), body mass index (for FW and FA), waist-to-hip ratio (for FA and MS), and duration of antiretroviral treatment (for FW).
authors.affiliation: Unité INSERM 330, Institut de Santé Publique, d'Epidémiologie et de Développement, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.
authors.forename: R
authors.initials: R
authors.lastname: Thiébaut
authors.forename: V
authors.initials: V
authors.lastname: Daucourt
authors.forename: P
authors.initials: P
authors.lastname: Mercié
authors.forename: D K
authors.initials: DK
authors.lastname: Ekouévi
authors.forename: D
authors.initials: D
authors.lastname: Malvy
authors.forename: P
authors.initials: P
authors.lastname: Morlat
authors.forename: M
authors.initials: M
authors.lastname: Dupon
authors.forename: D
authors.initials: D
authors.lastname: Neau
authors.forename: S
authors.initials: S
authors.lastname: Farbos
authors.forename: C
authors.initials: C
authors.lastname: Marimoutou
authors.forename: F
authors.initials: F
authors.lastname: Dabis
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use; D015331:Cohort Studies; D003430:Cross-Sectional Studies; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy; D017320:HIV Protease Inhibitors / Q000627:therapeutic use; D015497:HIV-1; D006801:Humans; D008060:Lipodystrophy / Q000150:complications / Q000453:epidemiology*; D008297:Male; D008659:Metabolic Diseases / Q000150:complications / Q000453:epidemiology*; D008875:Middle Aged; D015995:Prevalence; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use; D012307:Risk Factors
chemical_list: D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors